Scientists have a new strategy to enhance the anti-cancer immune response and slow tumor growth. The goal is to reprogram macrophages to eliminate tumor cells.
St. Jude scientists have completed the most complete analysis yet of the muscle and soft tissue tumor rhabdomyosarcoma.
For the second time in a row, the National Cancer Institute (NCI) has awarded
St. Jude the highest possible rank of “exceptional” during renewal of the hospital’s Comprehensive Cancer Center grant.
Researchers have solved a decades-old mystery about which mutations cause a rare, inherited bone marrow disorder. The answer may allow some children to avoid bone marrow transplantation.
St. Jude and the Institute for Health Metrics and Evaluation at the University of Washington are partnering to advance knowledge and understanding of childhood cancer around the world.
Like a mentor helping medical students choose between specialties, a protein complex helps shape the destiny of developing T cells, according to
St. Jude scientists.
St. Jude has completed the first genome sequencing of cancer survivors and found that 12 percent of childhood cancer survivors may have a higher risk of cancer.
St. Jude researchers have discovered that a quarter of medulloblastoma patients have the infant SHH-II subtype. These patients may respond to less aggressive forms of chemotherapy, sparing them a lifetime of side-effects from treatment.
St. Jude is the first WHO Collaborating Centre for Childhood Cancer. Read more about our exciting efforts to increase survival rates of children with pediatric cancer worldwide.
A protein has been identified that may help researchers target and kill cancer cells more effectively. Learn more about this exciting discovery.
A mutation has been identified that may help scientists determine how to manufacture drugs to better fight the influenza virus. Learn more about the advances of treating drug resistant viruses.
Scientists have discovered a new gene mutation that may help predetermine a child’s risk for developing ALL. Explore the latest breakthroughs.
St. Jude researchers recently discovered neurocognitive side-effects in patients may stem from leukemia itself, rather than solely from treatment-related causes. Read the latest.
One specific molecule might be the key to preventing infections in pediatric patients. Learn more about this new discovery.
As cancer survivorship increases, so do efforts to understand and strengthen social support and advice. Read the latest.
The chemotherapy drug cisplatin may help save a child’s life. But that same medication can also damage a child’s hearing.
A comprehensive analysis of the genes and mutations driving childhood cancer reveals just how different the disease is in children and adults.
St. Jude announces plans for a new, state-of-the-art advanced research center that will reinforce the scientific efforts of our faculty members. Learn more about this new addition to the
St. Jude community.
The Lebanese refugee crisis offers lessons in how to provide effective treatment for cancer and chronic diseases during emergencies.
Want young cancer survivors to stay active? Pilot study finds the chance to earn stickers, T-shirts and other rewards helps keep survivors moving.
The oncogene c-MYC drives high-risk neuroblastoma in some young cancer patients. The findings lay the groundwork for much needed precision medicines.
St. Jude quality improvement initiative that greatly increased the employee vaccination rate for pertussis, or whooping cough, offers a model for other health care institutions nationwide.
St. Jude scientists have discovered new germline variations in a tumor suppressor gene called TP53. Children with these variants are at risk of developing leukemia.